Combioxin receives Clinical Trial Authorization to initiate a first-in-man study with CAL02 in patients with severe pneumococcal pneumonia GENEVA, SWITZERLAND, 12 January 2016 – Combioxin SA is pleased to announce that - Bacterial pneumonia - Document - PDFSEARCH.IO

First Page	Meta Content
	Combioxin receives Clinical Trial Authorization to initiate a first-in-man study with CAL02 in patients with severe pneumococcal pneumonia GENEVA, SWITZERLAND, 12 January 2016 – Combioxin SA is pleased to announce that Add to Reading List Document Date: 2016-01-12 07:22:29 Open Document File Size: 92,33 KB Share Result on Facebook

Combioxin receives Clinical Trial Authorization to initiate a first-in-man study with CAL02 in patients with severe pneumococcal pneumonia GENEVA, SWITZERLAND, 12 January 2016 – Combioxin SA is pleased to announce thatAdd to Reading List